BIOMERICA INC BMRA
Last close
1.68
2026-10-23
Market cap
$7.7M
2026-05-31 share count
52-week range
1.45 - 3.02
Valuation FY2025 figures against the last close
P/S1.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.30
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- North America
- Asia
- Europe
- Middle East
- Other
| Region | FY2025 | FY2024 |
|---|---|---|
| North America | $1.5M | $1.7M |
| Asia | $1.4M | $1.7M |
| Europe | $1.1M | $1.3M |
| Middle East | $446.0K | $630.0K |
| Other | $15.0K | $8.0K |
As the company reported it, from the “SCHEDULE OF GEOGRAPHIC INFORMATION (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M | $5.3M | $5.4M | $5.3M | $18.9M | $7.2M | $6.7M | $5.2M | $5.6M | $5.8M |
| Cost of revenue | $4.1M | $4.8M | $4.8M | $4.9M | $15.9M | $6.8M | $5.0M | $3.9M | $3.8M | $3.8M |
| Gross profit | $362.0K | $498.0K | $611.0K | $446.0K | $3.0M | $366.3K | $1.7M | $1.3M | $1.8M | $2.0M |
| R&D | $788.0K | $1.0M | $1.5M | $1.6M | $1.8M | $2.2M | $1.9M | $1.7M | $1.4M | $1.1M |
| SG&A | $4.9M | $4.6M | $5.5M | $6.1M | $5.7M | $5.7M | $2.5M | $2.0M | $1.8M | $1.8M |
| Total operating expenses | $5.7M | $5.6M | $7.0M | $7.7M | $7.5M | $7.9M | $4.5M | $3.7M | $3.2M | $3.0M |
| Operating income | -$5.3M | -$5.1M | -$6.4M | -$7.2M | -$4.5M | -$7.5M | -$2.7M | -$2.4M | -$1.5M | -$954.6K |
| Interest expense | — | — | — | — | — | $367 | $9 | $47 | $37 | $282 |
| Pre-tax income | -$3.8M | -$5.0M | -$5.9M | -$7.1M | -$4.5M | -$7.4M | -$2.7M | -$2.4M | -$1.4M | -$908.6K |
| Income tax | $23.0K | $1.0K | $42.0K | $51.0K | $24.0K | $13.1K | $7.4K | $24.2K | $31.8K | — |
| Net income | -$3.8M | -$5.0M | -$6.0M | -$7.1M | -$4.5M | -$7.4M | -$2.7M | -$2.4M | -$1.5M | -$908.6K |
| EPS, basic | -1.30 | -2.16 | -2.84 | -0.50 | -0.36 | -0.62 | -0.26 | -0.26 | -0.17 | -0.11 |
| EPS, diluted | -1.30 | -2.16 | -2.84 | -0.50 | -0.36 | -0.62 | -0.26 | -0.26 | -0.17 | -0.11 |
| Shares, diluted (wtd. avg.) | 2.9M | 2.3M | 2.1M | 14.2M | 12.7M | 11.9M | 10.2M | 9.2M | 8.6M | 8.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.3M | $2.4M | $4.2M | $9.7M | $5.9M | $4.2M | $8.6M | $686.8K | $1.2M | $1.2M |
| Receivables | $785.0K | $731.0K | $947.0K | $722.0K | $774.0K | $1.5M | $1.8M | $1.5M | $799.9K | $1.1M |
| Inventory | $1.7M | $1.5M | $2.4M | $2.1M | $2.4M | $3.2M | $2.9M | $2.2M | $2.2M | $1.7M |
| Total current assets | $4.0M | $4.9M | $7.7M | $12.8M | $9.4M | $9.2M | $14.8M | $4.5M | $4.5M | $4.2M |
| Property, plant and equipment | $78.0K | $135.0K | $201.0K | $213.0K | $214.0K | $310.5K | $279.4K | $351.1K | $351.1K | $331.9K |
| Other intangibles | $209.0K | $228.0K | $212.0K | $165.0K | $170.0K | $294.8K | $168.7K | $107.2K | $98.9K | $174.5K |
| Total assets | $6.8M | $5.9M | $9.3M | $14.5M | $11.4M | $11.8M | $17.3M | $5.2M | $5.2M | $5.0M |
| Accounts payable | $377.0K | $295.0K | $560.0K | $344.0K | $736.0K | $431.0K | $833.4K | $1.0M | $687.0K | $352.0K |
| Total current liabilities | $2.5M | $1.7M | $2.2M | $1.9M | $2.0M | $1.3M | $1.5M | $1.3M | $896.8K | $528.9K |
| Total liabilities | $4.1M | $1.8M | $2.7M | $2.7M | $3.0M | $2.6M | $3.0M | $1.3M | — | — |
| Retained earnings | -$56.9M | -$53.2M | -$48.2M | -$42.2M | -$35.1M | -$30.5M | -$23.1M | -$19.6M | -$17.2M | -$15.7M |
| Total equity | $2.6M | $4.1M | $6.6M | $11.7M | $8.3M | $9.2M | $14.2M | $4.0M | $4.3M | $4.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.4M | -$3.8M | -$5.4M | -$5.5M | -$479.0K | -$5.3M | -$4.3M | -$2.2M | -$1.2M | -$722.9K |
| Depreciation and amortisation | — | — | — | $84.0K | $339.0K | $105.0K | $105.3K | $101.2K | $111.1K | $144.9K |
| Stock-based compensation | $476.0K | $460.0K | $837.0K | $1.2M | $1.3M | — | — | — | — | — |
| Capital expenditure | — | — | $51.0K | $64.0K | $57.0K | $135.9K | $33.6K | $101.1K | $130.3K | $96.1K |
| Investing cash flow | -$1.0K | -$37.0K | -$115.0K | -$78.0K | -$170.0K | -$295.6K | -$118.9K | -$171.1K | -$130.3K | -$96.1K |
| Financing cash flow | $2.3M | $2.1M | -$81.0K | $9.4M | $2.4M | $1.1M | $12.4M | $1.9M | $1.3M | $157.7K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-040851.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $5.6M | $5.2M | $6.7M | $7.2M | $18.9M | $5.3M | $5.4M | $5.3M | $4.5M |
| Gross profit | $2.0M | $1.8M | $1.3M | $1.7M | $366.3K | $3.0M | $446.0K | $611.0K | $498.0K | $362.0K |
| Net income | -$908.6K | -$1.5M | -$2.4M | -$2.7M | -$7.4M | -$4.5M | -$7.1M | -$6.0M | -$5.0M | -$3.8M |
Recent filings and events
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed Form 10-K
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.51B | 29.3x | 0.5% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| NTLA | Intellia Therapeutics, Inc. | $1.57B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $667.8M | — | — |
| MYGN | MYRIAD GENETICS INC | $556.7M | — | -1.6% |